

ASX Release

14th October 2016

SECOND CANINE RECEIVES TREATMENT IN TRIAL

*Second canine is treated with reformulated MPL in capsules
at Animal Referral Hospital in Homebush, NSW*

PharmAust Limited ("PharmAust") (ASX: PAA) is pleased to report that its exploratory Phase II canine trial has recruited and treated the second patient with cancer. This follows on from the first canine, which is being treated at the University of Cambridge (ASX announcement 19th September 2016). The second canine has commenced treatment with reformulated MPL capsules at the Animal Referral Hospital in Homebush, NSW. The trial is evaluating MPL capsules for efficacy against a variety of late-stage cancers in dogs. The dog in question is suffering from metastatic prostatic carcinoma with peritoneal effusion. MPL will be used in conjunction with the chemotherapy drug mitoxantrone.

The use of MPL in conjunction with chemotherapy has been an important step for PharmAust as earlier studies in dogs and mice have shown no increase of toxicity associated with chemotherapy in combination with MPL, as well as synergy between MPL and chemotherapy (Announcements dated 16.07.15 and 17.02.14).

As highlighted previously, the primary objective of the trial is to examine the effects of reformulated MPL capsules in different canine cancers with the aim of determining which cancers should be targeted in an expanded Phase II. It should be noted that many of the canine patients to be recruited in the trial may be suffering from late stage metastatic disease and will have failed "standard of care". As such, there would be no alternative treatment options available for the owners to implement for their pets. That being noted, any beneficial effect of the treatment would provide a strong case for pursuing MPL as a cancer therapy.

The new capsule formulation of MPL not only removes most palatability issues but also enables owners to treat their pets at home making the whole therapeutic regimen much easier on the pet and the owner. Treated dogs will be examined by the veterinary surgeon for tumour size and progression during the treatment period.

Principal Investigator, Angela Frimberger said: "In addition, we've recently expanded the availability of this compassionate use treatment to the Brisbane area. I'm delighted to be working with highly qualified veterinary clinicians in two Australian capital cities now, to enable them to offer this treatment for dogs that don't have any other options to treat their cancer. The new reformulated capsules are a huge leap forward in ease of handling and administering the medication, which further improves the quality of life for our patients."

We look forward to reporting progress when further animals are recruited and treated

For further details about PharmAust please contact:

Dr Roger Aston
Executive Chairman
Tel: 0402 762 204
rogeraston@pharmaust.com

Mr Robert Bishop
Executive Director
Tel: 0417 445 180
robertbishop@pharmaust.com

About The Animal Referral Hospital

The Animal Referral Hospital aims to provide veterinarians and their patients with the highest possible standards of veterinary care. They have two state of the art facilities, and specialists who are internationally recognised in their fields. Their nursing staff are dedicated to the care and well-being of pets in the hospital. Our staff are all devoted pet owners themselves, and pets are treated as our own, with every effort made to make their stay as comfortable as possible (<http://www.arhvets.com/>)